Diane King Hall is with me looking at a few more of the earnings here because there are many and we have more after the bell today. But let's start off with Kurig Dr. . Pepper.Good morning D. >> Yeah, we got some gains fizzing up here for Kurick Dr. . Pepper.Uh those shares higher off the back of its latest quarterly results have beat expectations on both the top and bottom line for Kurick Do Pepper in terms of earnings. They came in at 60 cents per share on an adjusted basis. So swinging into the black uh ...

Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard - 24/7 Wall St.[S&P 5006,840.40 -0.11%][Dow Jones48,869.20 +0.04%][Nasdaq 10024,790.20 +0.19%][Russell 20002,622.37 -0.23%][FTSE 10010,691.30 +0.07%][Nikkei 22557,665.30 +1.52%][Stock Market Live February 24, 2026: S&P 500 (SPY) Rebounding from Monday Disaster][Investing]# Hims & Hers Stumbles at the Open as Regulatory Damage Hits 2026 Outlook Hard### Quick ReadHims & Hers (HIMS) fell 6.6% in pre-market after Q1 2026 revenue guidan ...

Technologies][ZBRA]• Vol: 1,195,593-$24.099.43%$231.32[KKR][KKR]• Vol: 15,344,019-$8.998.89%$92.19 Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall - 24/7 Wall St.[S&P 5006,852.00 +0.06%] [Dow Jones48,925.20 +0.15%][Nasdaq 10024,773.40 +0.12%][Russell 20002,626.72 -0.07%][FTSE 10010,679.60 -0.04%][Nikkei 22557,615.30 +1.43%][Investing]# Hims & Hers Snaps EPS Losing Streak but Shares Still in Free Fall### Quick ReadHims & Hers (HIMS) beat Q4 EPS by 60% and delivered $2.35B full year revenue, ...

Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers Stock Drops. Why Earnings Are Underwhelming Investors.By [Mackenzie Tatananni]ShareResize---ReprintsIn this artic ...

US stock futures ticked higher on Tuesday, attempting to stabilize after Wall Street gauges kicked off the final stretch of February with steep losses led by fears of AI disruption and tariff whiplash. Dow Jones Industrial Average futures (YM=F) rose 0.1%. Contracts on the S&P 500 (ES=F) climbed roughly 0.2%, while Nasdaq 100 futures (NQ=F) added 0.3%. The cautious rebound follows a sharp sell-off on Monday as investors grappled with renewed concerns that rapid advances in AI could disrupt broad swaths ...

US stock futures nudged higher on Tuesday, struggling to recover from steep losses led by fears of AI disruption as President Trump's new global tariff came into effect. Dow Jones Industrial Average futures (YM=F) were up about 0.2%. Contracts on the S&P 500 (ES=F) hovered above the flatline. Nasdaq 100 futures (NQ=F) added 0.3%, as AMD (AMD) shares jumped about 10% after the chipmaker entered a deal to provide Meta (META) with a huge amount of GPUs for the Facebook owner's AI buildout. The cautious reb ...

The telehealth platform posted a quarterly profit of $20.6 million, down from $26 million a year earlier. ...

Core Viewpoint - Hims & Hers Health reported mixed financial results for the fourth quarter, beating earnings per share estimates but missing revenue expectations, leading to stock volatility. Financial Performance - Fourth-quarter revenue was $617.82 million, missing analyst estimates of $619.22 million [1] - The company reported earnings of eight cents per share, exceeding estimates of three cents per share [1] - Total revenue increased by 28% year-over-year, with subscribers growing to over 2.5 million, a 13% increase from 2025 [2] - Gross margin for the fourth quarter was 72%, down from 77% in the same quarter of 2024 [2] - Operating cash flow was $61.3 million, while free cash flow was negative at $2.6 million [3] - The company ended the quarter with $228.62 million in cash and cash equivalents [3] Future Guidance - Hims & Hers expects first-quarter revenue between $600 million and $625 million, below estimates of $653.12 million [4] - Full-year 2026 revenue guidance is set at $2.7 billion to $2.9 billion, compared to estimates of $2.74 billion [4] Strategic Outlook - The company aims for at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, supported by a strong balance sheet and operating cash flow [5] - Plans include investing in scaling new specialties, advancing technology and infrastructure, and expanding internationally [5] Stock Performance - Hims & Hers shares initially traded lower after the earnings report, showing volatility in after-hours trading, down 0.64% at $15.41 [7]

Group 1 - Hims & Hers, a telehealth provider known for compounded weight-loss drugs, has issued a weak outlook for the future [1] - The company is facing challenges that may impact its growth trajectory and financial performance [1] - Investors are concerned about the sustainability of the company's business model in a competitive market [1] Group 2 - The telehealth industry is experiencing increased scrutiny and regulatory challenges, which may affect companies like Hims & Hers [1] - Market dynamics are shifting, with a growing emphasis on transparency and efficacy in telehealth services [1] - The outlook for telehealth providers may be influenced by broader healthcare trends and consumer preferences [1]

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 7 Oversold Pharma Stocks to Buy Now. Hims & Hers Health, Inc. (HIMS) Expands Global Footprint With Eucalyptus Acquisition Hims & Hers Health, Inc. (NYSE:HIMS) is one of the most oversold stocks. HIMS declared on February 19, 2026, that it has finalized a deal to purchase Eucalyptus for a maximum of $1.15 billion, subject to usual adjustments. The remaining consideration will consist of guaranteed deferred payments over the next 18 months and subsequent e ...